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Poster Session I S251of survival at 5 years without requiring HSCT was only 28.11/-
8.8%.We conclude that only a minority of patients with CBF leuke-
mia will be long term survivors relying exclusively on conventional
chemotherapy. Early use of HSCT for high-risk CBF-AML should
be pursued in clinical trials.266
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Introduction: Standard myeloablative conditioning combined bu-
sulphan (16 mg/kg) and cyclophosphamide (120 mg/kg) (BU-CY)
is associated with high non-hematologic toxicity, significantmorbid-
ity and mortality. Regimen combined fludarabin (125 mg/m2), bu-
sulphan (12 mg/kg) and thymoglobuline (6 mg/kg) (FLU-BU12-
TG) might be less toxic and safer despite the myeloablative dose of
busulphan. Retrospective study compared the results of allogeneic
SCT after those two regimens in the patients with AML.
Patients andMethods: 21 patients with AMLwere allografted after
BU-CY and 10 ones after FLU-BU12-TG. There were no differ-
ences between those groups in: the number of patients allografted
in complete remission of AML, gender and age of patients and do-
nors, the quality of graft and follow-up period. Significantly more
patients in the group of FLU-BU12-TG were allografted from un-
related (90% vs. 19%; P0,00018) and HLA mismatched donor
(50% vs. 0%; P0,0004). The incidence and risk of acute and chronic
graft versus host disease (GVHD), AML relapse, non-relapse
(NRM) and overall mortality, the probability of event-free (EFS)
and overall survival (OS) were analysed and compared in both con-
ditioning groups.
Results:No significant differences were found between the BU-CY
and FLU-BU12-TG in the incidence of acute (38% vs. 50%; P0,53)
or chronic GVHD (44% vs. 33%; P0,58), AML relapse (24% vs.
11%; P0,43), NRM (33% vs. 10%; P0,17), overall mortality (52%
vs. 20%; P0,087), the probability of 2-year EFS (50% vs. 89%;
P0,19) and OS (55% vs. 80%; P0,28).
Conclusion: Regimen FLU-BU12-TG seems to be a feasible
alternative approach to the patients allografted for AML and requir-
ing pretransplant cytoreduction but standard myeloablative condi-
tioning would be associated with the significant risk of severe
complications.LYMPHOMA/MULTIPLE MYELOMA
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MAINTENANCE THERAPY WITH LOW DOSE THALIDOMIDE, DEXAMETH-
ASONE AND CLARITHROMYCIN (BLT-D) FOLLOWING AUTOLOGOUS
TRANSPLANT (ASCT) FOR MULTIPLE MYELOMA (MM)
Holmberg, L.1,2, Gooley, T.1, Becker, P.1,2, Maloney, D.1,2,
Bensinger, W.1,2 1Fred Hutchinson Cancer Research Center, Seattle,
WA; 2University of Washington, Seattle, WA
Since relapse remains amajor problem after ASCT forMM, inves-
tigators have looked at the role of maintenance therapy post trans-
plant. It is not yet established which maintenance regimen is best
or the optimal duration for therapy.M. Coleman et al (Leuk&Lym-
phoma 43: 1777, 2002), pioneered a well tolerated regimen of BLT-
D with high CR/PR rates (93%) in MM patients. These results sug-
gested that BLT-D regimen may have a role as maintenance therapy
after ASCT.Twenty-seven patients (stage II, n-8; stage III, n5 19 by
Durie-Salmon criteria) were treated. Before ASCT, 52% had re-
ceived Thalidomide, 26% had received VAD, and 37% were treated
withmore than one regimen (range 2-4) prior tomobilization of stem
cells. At the time of ASCT, 20% were in CR/near CR. Following
ASCT, all patients received conditioning with melphalan 200mg/m2. After recovery from conditioning toxicity, between 30-120
days post ASCT (median 101 days (range 33-119), patients were
treated with Clarithromycin 250 mg po bid, dexamethasone 20 mg
po weekly, and thalidomide beginning dose 50 mg po daily days 1-
14, then increased to 100 mg po daily. After one year of combination
therapy, dexamethasone andClarithromycin were stopped. Thalido-
mide was given as long as tolerated until disease progression. Aspirin
and low dose coumadin were used as DVT prophylaxis. Six patients
(22%) discontinued thalidomide for progressive disease.Neuropathy
was the most common toxicity: 12 patients (44%) stopped because of
unimproved$ grade 2 toxicity and 7 (26%) required dose reduction
of thalidomide. One patient stopped therapy because of rash.Median
time to stoppingThalidomidewas 13.5months (range 6-42months).
Nine patients (33%) required dose reduction of dexamethasone. The
number of infections included: pneumonia (n5 3), upper respiratory
viral infection (n5 2), sinusitis (n5 1), and bronchitis (n5 3). Seven
patients have died due to: infection (n 5 1), MM (n 5 5), and com-
plications of second ASCT (n 5 1). As of 7/12/10, 20 patients
(74%) are alive and 13 (48%) are alive without disease progression.
Median follow-up is 59.5 months (38-73 months). In summary,
BLT-D can be given post ASCT. Peripheral neuropathy was the
most common significant toxicity that required patients to stop ther-
apy. With a median follow-up of 59.5 months from ASCT, 48% of
the patients are alive without evidence of disease progression and
74%are alive. Randomized studies to compare onemaintenance reg-
imen to another are needed post ASCT.268
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Since relapse remains a major cause for treatment failure after
ASCT for MM, the role of maintenance therapy has been studied.
Neither the best maintenance regimen nor optimal duration of ther-
apy post ASCT has been established. Niesvizky R et al (Blood 111:
1101-09, 2008) reported on the efficacy of BIRD as front-line ther-
apy for MM, with 90% objective response rate and manageable tox-
icities. Thus, it seemed reasonable to study such a regimen as
maintenance therapy post ASCT. Thirty-one patients (Stage I/II,
n5 13 and stage III, n5 18 by Durie-Salmon criteria) were treated.
Before ASCT, 81% received Thalidomide, 23% Lenalidomide, and
45% Bortezomib; 58% were treated with . 1 regimen (range 1-4)
prior to mobilization. Cytogenetic abnormalities included: poor
prognosis (23%), del13 by FISH (13%), t11,14 (10%), and tris 11/
11q (10%). PBSC were collected in 80% of patients off chemother-
apy/growth factor. At ASCT, 42% of patients were in PR, 6.5% had
SD, and 6.5% had progressive disease. All patients were conditioned
with melphalan 200mg/m2; one patient was treated after planned
tandem. At median of 113 days (range 49-133) and after recovery
from acute toxicity of ASCT, patients were treated with Clarithro-
mycin 250 mg po bid, Dexamethasone 20 mg po weekly, and Lena-
lidomide 25 mg po daily day 1-14 every 21 day cycles. After one year
of combination therapy, dexamethasone was tapered off and Clari-
thromycin was stopped. Lenalidomide was continued as long as tol-
erated until disease progression. All patients were treated daily with
coated aspirin (325 mg) for DVT prophylaxis. One patient devel-
oped DVT/PE. Five patients stopped therapy for disease progres-
sion and 11 stopped for significant toxicity (protracted . 30 days
peripheral neuropathy grade 3 (n 5 2), VZV/PCP/viral pneumonia
(n5 3), protracted neutropenia (n5 3), MDS 5q (n5 1), cellulitis (n
5 1), and leukocytic vasculitis (n 5 1)). Peripheral neuropathy and
neutropenia were most common non-infectious toxicities. As of 9/
2010, all patients remain alive and twenty patients (65%) remain
alive without disease progression; with median follow-up of 33
months (range 20-45) from transplant. In summary, BIRD can be
given post ASCT. Peripheral neuropathy and neutropenia are
most common non-infectious toxicities. With median follow-up of
33 months, all patients remain alive and 65% remain alive without
